2026 Volume: 02 Issue: 11 www.ijrpa.com ISSN 2456-9995 Review Article

International Journal Research Publication Analysis

Page: 01-10

ROLE OF BACOPA MONNIERI IN ANXIETY AND DEPRESSION: A COMPREHENSIVE REVIEW

*[1]Deepak Weldar, [2]Divyani Soni, [3]Dr. Shruti Rathore

[1]Student of Choksey college of pharmacy Bilaspur C.G.

[2]Assistant Professor Department of Pharmacognosy CCP Bilaspur C.G.

[3]Principal Choksey college of pharmacy Bilaspur C.G.

Article Received: 15 October 2026

Article Revised: 04 November 2026

Published on: 23 November 2026

***Corresponding Author: Deepak Weldar**

Student of Choksey college of pharmacy bilaspur C.G.

DOI: https://doi-doi.org/101555/ijrpa.7155

1. ABSTRACT AND INTRODUCTION

1.1 Abstract

Bacopa monnieri, commonly known as Brahmi or water hyssop, is a creeping medicinal herb traditionally used in Ayurveda as a *medhya rasayana*, a preparation associated with memory and mental function.

The plant contains diverse phytochemicals, particularly dammaranetype triterpenoid saponins collectively described as bacosides, along with alkaloids, flavonoids, sterols, glycosides and other constituents.

Preclinical studies suggest possible neuroprotective, antioxidant, antiinflammatory and neuromodulatory actions. These mechanisms have led to interest in its possible effects on stress, anxiety-related behaviour and depressive-like behaviour.

Human evidence specifically addressing anxiety and depression remains limited.

KEYWORDS: *Bacopa monnieri*, Brahmi, Bacosides, Anxiety, Depression, Neuroprotection, Ayurveda, Herbal medicine.

1.2 INTRODUCTION

Anxiety and depressive disorders are common mental health conditions that can affect emotions, thinking, sleep, physical health and daily functioning.

Their development is multifactorial and may involve genetic, psychological, environmental, neurochemical and inflammatory influences.

Established treatments include evidence-based psychological therapies and, when appropriate,

prescribed medicines. Herbal products are also being investigated, but traditional use or laboratory activity alone does not establish clinical effectiveness.

Bacopa monnieri has a long history of use in Ayurvedic medicine. Modern research has focused mainly on cognition and memory, while its possible role in anxiety and mood has received comparatively less clinical study. The purpose of this review is to examine the available evidence without treating Bacopa as a proven replacement for standard mental-health care.

Bacopa monnieri (commonly known as Brahmi or water hyssop) is a perennial, creeping herb native to wetland and marshy areas across Asia, Australia, Europe, Africa, and the Americas. In traditional Ayurvedic

medicine, it is revered as a potent brain tonic and rejuvenative herb. Bacopa (*Bacopa monnieri*, also known as Brahmi, water hyssop, or herb of grace) is a small creeping medicinal herb.



Figure 1: Bacopa monnieri (L.) Wettst. showing succulent creeping stems, opposite leaves, and solitary pale flower in its natural wetland habitat.



2. Botanical Description and Medicinal Uses

2.1 Botanical Description

Bacopa monnieri is a small, succulent, creeping perennial herb commonly found in wet, marshy and seasonally waterlogged habitats.

The stems are soft, prostrate and capable of rooting at the nodes, allowing the plant to spread along moist ground.

The leaves are simple, fleshy, opposite and sessile or nearly sessile. They are generally oblong to spatulate with smooth margins.

The flowers are small and usually solitary in the leaf axils. They are commonly pale blue, whitish or purplish, with a tubular corolla.

The fruit is a small capsule containing numerous minute seeds.



Figure 2: Brahmi Plant (Bacopa monnieri) morphological parts — Flower (Attracts pollinators), Bud (Develops into flower), Leaf (Performs photosynthesis), Stem (Supports the plant), and Root (Absorbs water and minerals).

The whole plant or aerial parts are used in traditional preparations. Correct botanical identification is important because the common name "Brahmi" is also used for other plants, including *Centella asiatica*.

2.2 Traditional and Medicinal Uses

- **Traditional cognitive use:** Ayurveda describes Brahmi as a *medhya rasayana*, traditionally used to support memory, learning and intellect.
- **Calming use:** Traditional practice has included its use in preparations intended to promote

calmness and support mental well-being.

- **Neuroprotective research:** Extracts and isolated constituents are being studied for effects on neuronal function and cellular stress.
- **Antioxidant potential:** Laboratory studies report activity in assays related to free-radical scavenging and oxidative stress.
- **Anti-inflammatory potential:** Experimental findings suggest that some extracts may influence inflammatory pathways.
- **Important limitation:** These traditional and experimental uses do not prove that Bacopa treats clinical anxiety or depression in humans.

3. Phytochemical Constituents of Bacopamonnieri

Phytochemical Constituents of *Bacopa monnieri*

Phytochemical Group	Key Constituents & Pharmacological Relevance
Bacosides	Main triterpenoid saponins (Bacoside A, Bacoside B). Neuroprotective, enhances cognitive function, improves memory acquisition and retention, exhibits antioxidant activity in the brain.
Bacopasides & Bacopasaponins	Various dammarane-type saponins (Bacopaside I-XII, Bacopasaponin A-G). Contribute to the nootropic effects, show anxiolytic properties, adaptogenic, modulates neurotransmitter levels.
Alkaloids	Brahmine, herpestine, and other minor alkaloids. Potentially contribute to the overall sedative and tranquiizing effects, although less studied than saponins.
Flavonoids	Luteolin, apigenin, and glycosides. Free radical scavenging, potent antioxidant, anti-inflammatory, helps maintain vascular integrity.
Phenolic Compounds	Phenolic acids, coumarins. Strong antioxidant properties, protects against cellular damage, contributes to overall plant defense mechanisms.
Sterols & Triterpenes	β-sitosterol, stigmasterol, lupeol, botulinic acid. Structural components, potential anti-inflammatory and cholesterol-lowering effects, precursors to saponins.
Glycosides	Various glycosidic compounds (apart from saponins and flavonoids). Involved in carbohydrate storage, potentially having diverse, less characterized biological functions.
Other Constituents	Includes alcohols (e.g., mannitol), hydrocarbons, and various minerals. Essential components, though not directly linked to major pharmacological actions, support plant metabolism.

Phytochemical Standardization

Standardization is important because two products labelled as Bacopa may not contain equivalent amounts or proportions of active constituents.

Research reports often quantify bacosides or selected saponins, but analytical methods differ. Therefore, the stated percentage of "bacosides" should not automatically be considered comparable between products unless the assay method and marker compounds are specified.

For research and quality control, authenticated plant material, a defined extraction procedure, chromatographic fingerprinting and validated quantitative assays are useful. These measures improve reproducibility and help distinguish genuine *Bacopa monnieri* from adulterated or substituted material.

4. Proposed Mechanisms Related to Anxiety andDepression

4.1 Possible Mechanisms of Action

The mechanisms through which Bacopa may influence anxiety- or depression-related pathways are not fully established. Much of the mechanistic evidence comes from cell and animal studies, and should not be interpreted as proof of a clinical effect in people.

- **Antioxidant action:** Bacopa constituents may help limit oxidative damage by influencing free-radical activity and endogenous antioxidant defence systems.
- **Neurotransmitter modulation:** Experimental studies suggest possible effects on cholinergic, serotonergic, dopaminergic and GABA-related signalling. The relevance and magnitude of these effects in humans remain uncertain.
- **Stress-response pathways:** Animal research has explored whether Bacopa extracts influence physiological responses to stress, including pathways associated with the hypothalamic-pituitaryadrenal (HPA) axis.
- **Anti-inflammatory effects:** Some preclinical findings indicate modulation of inflammatory mediators, which are being studied in relation to brain function and mood.
- **Neuroprotective effects:** Bacosides have been investigated for effects on neuronal integrity, synaptic function and cellular responses to injury.

Proposed Mechanism Diagram



4.2 Potential Effects on Anxiety and Depression

Anxiety-related evidence

Traditional Ayurvedic use and preclinical studies provide a rationale for investigating Bacopa as a calming or anxiolytic botanical.

Animal studies have reported changes in behavioural tests used to investigate anxiety-like responses. Such tests are indirect models and cannot reproduce the full experience or diagnosis of human anxiety disorders.

In a randomized, double-blind, placebo-controlled study of older adults , a standardized Bacopa extract (300 mg/day for 12 weeks) was associated with a reduction over time in combined state and trait anxiety scores compared with the placebo pattern.

The trial involved healthy older volunteers and was not designed to establish Bacopa as a treatment for a diagnosed anxiety disorder.

Larger, well-designed clinical trials are required.

Depression-related evidence

Preclinical research has examined possible antidepressant-like effects of Bacopa extracts and isolated constituents in animal models.

Proposed explanations include antioxidant and anti-inflammatory activity and possible modulation of neurotransmitter systems involved in mood regulation.

In the same small older-adult clinical trial , depressive symptom scores measured using the CESD-10 decreased over time in the Bacopa group relative to placebo.

This finding is preliminary. A symptom-scale change in a small study of older adults does not demonstrate efficacy for major depressive disorder or other clinical depressive disorders.

At present, evidence is insufficient to recommend Bacopa as a standalone treatment for anxiety or depression.

Overall interpretation

The available evidence is hypothesis-generating. Bacopa may have biological activities relevant to stress and mood, but human studies specifically designed around diagnosed anxiety and depressive disorders are limited.

Clinical decisions should be based on established care, individual assessment and consultation with a qualified healthcare professional.

5. Evaluation Methods and PharmacologicalApplications

5.1 Evaluation Methods of Bacopa monnieri

- **Macroscopic evaluation:** Examination of the plant's appearance, leaf arrangement, stem characteristics, flowers, colour, odour and general morphology.
- **Microscopic evaluation:** Study of leaf, stem and other plant tissues under a microscope to support identification and detect adulteration.
- **Phytochemical evaluation:** Qualitative and quantitative tests to identify saponins, bacosides, flavonoids, alkaloids, phenolics and other constituents.
- **Physicochemical evaluation:** Measurement of moisture

content, total ash, acid-insoluble ash and extractive values to assess crude-drug quality.

- **Chromatographic evaluation:** TLC/HPTLC and HPLC methods can be used for chemical fingerprinting and estimation of selected bacosides or saponin markers.
- **Antioxidant evaluation:** In-vitro assays such as DPPH, ABTS, FRAP and related methods may be used to estimate antioxidant capacity. Results depend on assay conditions and do not directly predict clinical benefit.
- **Neuropharmacological evaluation:** Cell-based and animal models may investigate neuronal protection, neurotransmitterrelated activity, stress responses and anxiety-like or depressive-like behaviours.
- **Clinical evaluation:** Human trials should use validated symptom measures, appropriate diagnostic criteria, adequate sample sizes, placebo or active comparators, safety monitoring and transparent reporting.

5.2 Pharmacological Applications Under Investigation

- **Cognitive function:** Studied for possible effects on memory, learning and information processing.
- **Anxiety and stress:** Investigated for potential calming and stress-response effects; clinical evidence remains limited.
- **Mood and depression:** Preclinical findings and preliminary human observations warrant further study, not therapeutic claims.
- **Neuroprotection:** Studied for antioxidant and cellular protective properties.
- **Anti-inflammatory activity:** Experimental research has explored effects on selected inflammatory pathways.
- **Antioxidant activity:** Extracts have shown activity in several laboratory antioxidant assays.

6. Safety, Limitations and Research Needs

6.1 Safety and Tolerability

Bacopa products are not interchangeable: extract strength, plant part, standardization and quality may differ substantially.

Reported adverse effects are commonly gastrointestinal and may include nausea, abdominal cramps, increased stool frequency or diarrhoea.

Headache, dizziness and dry mouth have also been reported.

People who are pregnant or breastfeeding should avoid medicinaldose use unless specifically advised by a qualified clinician, because adequate safety information is lacking.

People taking prescription medicines or managing chronic conditions should consult a healthcare professional before using Bacopa. Potential interactions and effects on drug-metabolizing enzymes have been discussed in research, but their clinical significance is not fully defined.

Do not stop or reduce prescribed antidepressants, anti-anxiety medicines or psychotherapy on the basis of herbal-product information.

6.2 Limitations of Current Evidence

- Many mechanistic findings come from laboratory or animal studies rather than human clinical trials.
- Clinical studies often focus on cognition, with anxiety or mood included as secondary outcomes.
- Studies may differ in extract composition, dose, duration, participant age and outcome measures.
- Small sample sizes and short follow-up periods limit confidence in the results.
- Evidence from healthy volunteers cannot automatically be generalized to people with diagnosed anxiety or depressive disorders.
- More independent, adequately powered randomized controlled trials are needed.

6.3 Future Research

Future studies should use authenticated and chemically standardized extracts, clearly report bacoside profiles, recruit participants with well-defined clinical diagnoses, and measure both benefits and adverse effects over an adequate period. Researchers should also investigate dose-response relationships, long-term safety, interactions with commonly prescribed

medicines and whether any observed effects are clinically meaningful.

7. DISCUSSION, CONCLUSIONS AND REFERENCES

7.1 DISCUSSION

Bacopa monnieri is an established medicinal plant in Ayurvedic tradition and contains a complex mixture of bioactive constituents, particularly triterpenoid saponins known as bacosides. Research has explored its antioxidant, anti-inflammatory and neuroprotective properties, alongside possible effects on neurotransmitter and stressrelated pathways.

These findings provide a scientific rationale for investigating Bacopa in relation to anxiety and depression. However, the strength of evidence differs across research levels. Laboratory and animal studies can help identify possible biological pathways, but they cannot establish that a botanical product is effective for a human psychiatric disorder.

A small randomized controlled trial in older adults reported reductions in anxiety and depressive symptom scores during 12 weeks of standardized Bacopa use. This is a relevant preliminary observation, but the study was not conducted in a clinical population diagnosed with anxiety or depression. The result therefore needs confirmation in larger and more targeted trials.

Overall, *Bacopa monnieri* is a promising subject for further neuropsychopharmacological research, but current evidence does not support presenting it as an established treatment for anxiety or depression.

7.2 CONCLUSION

Bacopa monnieri (Brahmi) is a traditional medicinal herb containing bacosides and several other phytochemical constituents. Experimental studies suggest antioxidant, anti-inflammatory and neuroprotective activities that may be relevant to brain function and mood.

A limited human evidence base has reported changes in anxiety and depressive symptom scores, but the findings are preliminary and do not establish efficacy for diagnosed disorders.

Further high-quality clinical trials are required to determine its effectiveness, appropriate formulation, dose, duration and long-term safety. Bacopa should not replace evidence-based treatment for anxiety or depression.

7.3 REFERENCES

1. Calabrese, C., Gregory, W.L., Leo, M., Kraemer, D., Bone, K. and Oken, B. (2008). Effects of a standardized *Bacopa monnieri* extract on cognitive performance, anxiety, and depression in the elderly: a randomized, doubleblind, placebo-controlled trial. *Journal of Alternative and Complementary Medicine*, 14(6), 707–713. https://doi.org/10.1089/acm.2008.0018
2. Russo, A. and Borrelli, F. (2005). *Bacopa monniera*, a reputed nootropic plant: an overview. *Phytomedicine*, 12(4), 305–317.
3. Kuruvalli, G., Wankhade, I., Wankhede, S., Ramesh, S.B., Narayanaswamy, C.K., Munikrishnappa, G.N. and Reddy, V.D. (2023). A comprehensive review on the ethno-medicinal and pharmacological properties of *Bacopa monnieri*. *Pharmacognosy Reviews*, 17(34), 418–425. https://doi.org/10.5530/phrev.2023.17.17
4. Sudhakaran, M.V. (2020). Botanical pharmacognosy of *Bacopa monnieri* (Linn.) Pennell. *Pharmacognosy Journal*, 12(6 Suppl.), 1559–1572. https://doi.org/10.5530/pj.2020.12.214
5. Walker, E.A. and Pellegrini, M.V. (2023). *Bacopa monnieri*. In: StatPearls. StatPearls Publishing. National Center for Biotechnology Information Bookshelf.
6. Pharmacological attributes of *Bacopa monnieri* extract: Current updates and clinical manifestation. (2022). *Frontiers in Nutrition*. https://doi.org/10.3389/fnut.2022.972379
7. *Bacopa monnieri*: Preclinical and clinical evidence of neuroactive effects, safety of use and the search for improved bioavailability. (2025). Review article available through PubMed Central